IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/517,319

Applicant: UNIVERSITÉ LAVAL

Filed: July 15, 2005

Tifle: CHEMOTATIC FFACTOR INHIBITOR FOR MODULATING

INFLAMMATORY REACTIONS

Group Art Unit: 1656

TSAY, Marsha M. Examiner: Attv. Docket No.: 6013-149US

INFORMATION DISCLOSURE STATEMENT FEE REOUIRED

COMMISSIONER FOR PATENTS PO Box 1450

Alexandria, VA 22313-1450

Sir

Submitted herewith on a PTO/SB/08B form is a document known to applicant in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. § 1.56.

The Commissioner is hereby authorized to charge the fee of \$180.00, required for late submission of this Information Disclosure Statement in accordance with 37 CFR 1.97(d), to Deposit Account Number 19-5113. The Commissioner is further authorized to charge any fees which may be required or credit any overnayment to the Deposit Account No. 19-5113.

Applicant further submits that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

In accordance with 37 CFR 1.97(h), the submission of the present information is not to be construed as an admission that such information is, or is considered to be material to patentability.

The Examiner is kindly requested to consider this reference during the examination of the above-identified application, making the reference of record.

Respectfully submitted,

December 15, 2006

Date

Agent of the Applicant

Marie-Hélène ROCHON, Reg. No. 57,566

OGILVY RENAULT LLP/S.E.N.C.R.L., s.r.l. 1981 McGill College, Suite 1600 Montreal, Quebec, Canada H3A 2Y3 Tel.: (514) 847-4639

Encl. - Form PTO/SB/08B (1 page) + 1 document (4 pages)

PTC/SB/048 (09-06)

Approved for use through 03/31/2007. ORIS 0651-003.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid CMB control number Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as menty abouts as necessary)					Application Number 10/517,319				
					Filing Date	July 15, 2005 Philippe A. TESSIER			
					First Named Inventor				
					Art Unit	1656			
					Examiner Name	Marsha M. TSAY			
Sheet 1			of	1	Attorney Docket Number	6013-149US			
							_		
				NON PAT	ENT LITERATURE DOC	CUMENTS			
Examiner Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
						1 in adherent human leukocytes zine, 1996, 2: 1259-1262			
							Т		
							_		
							Ī		

Application Number

Under the Paperwork Reduction Act of 1995, no persons are required to resp

Substitute for form 1443/PTO

Examiner	Date
Signature	Considered

"EXAMINER: Initial it reference considered, whether or not cladon is in conformance with MPEP 609. Drew like through cladion if not in conformance and not considered. Include copy of this form with next communication to applicant

conceives. Notice doly of this that an earl collegementation is apparent to an explaint and a supplied to a finite product of the control of the supplied of the control of the supplied of the control of the supplied of the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.